Kenneth R. Trammell, a director at Universal Technical Institute Inc . (NYSE:UTI), recently executed a significant stock transaction. On November 27, Trammell sold 30,000 shares of the company's common stock. The transaction comes as UTI trades near its 52-week high of $26.43, with the stock delivering impressive returns of over 106% year-to-date. According to InvestingPro analysis, the stock is currently showing overbought signals. The shares were sold at a weighted average price of $25.9151, resulting in a total transaction value of approximately $777,453. The sale was conducted over multiple transactions, with prices ranging from $25.59 to $26.16. Following this sale, Trammell now holds 128,205 shares of Universal Technical Institute, which currently has a market capitalization of $1.39 billion and trades at a P/E ratio of 33.3x.
Additionally, Trammell exercised stock options to acquire 30,000 shares at a price of $3.14 per share, which he subsequently sold on the same day. This transaction highlights Trammell's ongoing engagement with the company's stock. For deeper insights into UTI's valuation and 12+ additional exclusive tips, check out the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Universal Technical Institute (UTI) demonstrated robust growth with a 21% revenue increase to $733 million and a net income of $42 million in the fiscal year 2024. The company also reported a 10% rise in average full-time active students and a significant 60% surge in adjusted EBITDA, reaching $103 million. Looking ahead, UTI is entering Phase 2 of its North Star strategy, focusing on campus expansion, the introduction of new programs, and operational optimization.
For the fiscal year 2025, UTI projects revenue in the range of $800-$815 million and plans to roll out new programs and campuses. Rosenblatt Securities recently increased its price target for UTI shares to $30.00, up from a previous $22.00, citing the company's impressive performance and the expanding skills gap as key contributing factors. The firm reiterated a Buy rating on the stock, indicating potential for further growth.
These recent developments underscore Rosenblatt's confidence in UTI's strategic positioning to meet the increasing demand for skilled professionals and continue its growth trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.